Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) reached 241.8% versus a 1-year low price of $0.43. The stock was last seen 4.96% higher, reaching at $1.48 on Thursday, May 18, 2017. At recent session, the prices were hovering between $1.37 and $1.55. This company shares are 220.95% off its target price of $4.75 and the current market capitalization stands at $48.17M. The recent change has given its price a 4.02% lead over SMA 50 and -67.69% deficit over its 52-week high. The stock witnessed 14.73% gains, 62.64% gains and 48% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BLPH’s volatility during a week at 10.11% and during a month it has been found around 8.18%.

Bellerophon Therapeutics, Inc. (BLPH) Top Holders

Institutional investors currently hold around $21 million or 57.1% in BLPH stock. Look at its top three institutional owners. New Mountain Vantage Advisers, L.L.C. owns $14.91 million in Bellerophon Therapeutics, Inc., which represents roughly 30.95% of the company’s market cap and approximately 71% of the institutional ownership. Similar statistics are true for the second largest owner, Boxer Capital, Llc, which owns 1,857,143 shares of the stock are valued at $2.62 million. The third largest holder is Fmr Llc, which currently holds $1.61 million worth of this stock and that ownership represents nearly 3.35% of its market capitalization.

Bellerophon Therapeutics, Inc. 13F Filings

At the end of 03/31/2017 reporting period, 6 institutional holders increased their position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by some 859,096 shares, 8 decreased positions by 2,031,941 and 5 held positions by 11,980,192. That puts total institutional holdings at 14,871,229 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 269,985 shares while 6 institutional investors sold out their entire positions totaling 1,956,618 shares.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Insider Trades

Multiple company employees have indulged in significant insider trading. Bellerophon Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director, 10% Owner Luehring Jens has acquired 20,000 shares of Bellerophon Therapeutics, Inc. (BLPH) in trading session dated Dec. 09, 2016. These shares are worth $11,200 and were traded at $0.56 each. The SEC filing shows that Peacock Jonathan M performed a purchase of 5,000 shares. The President and CEO added these shares by way of transaction on May. 17, 2016. The company’s shares were assimilated at $1.37 per share worth to an investment of some $6,850 on account of Peacock Jonathan M.

President and CEO, Peacock Jonathan M, purchased 20,300 common shares of Bellerophon Therapeutics, Inc. (BLPH) in the open market. In a transaction dated Dec. 16, 2015, the shares were bought at an average price of $2.75, giving away a sum of $55,825. After this purchase, 51,727 common shares of BLPH are directly owned by the insider, with total stake valued at $76,556.

In the transaction dated Aug. 19, 2015, the great number of shares acquired came courtesy the President and CEO; Peacock Jonathan M added a total of 5,000 shares at an average price of $5.48, amounting to approximately $27,400. The insider now directly owns 31,427 shares worth $46,512.

Bellerophon Therapeutics, Inc. (BLPH) Analyst Guide

Not many analysts have released their opinion on Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

Previous articleFortress Biotech, Inc. (NASDAQ:FBIO) held by 13 SEC 13F Filers
Next article44 hedge funds sold their entire positions in TerraVia Holdings, Inc. (NASDAQ:TVIA)